Psychedelic Infusion Therapy for Depression and Anxiety

72% of patients experience a clinically 

meaningful response to psychedelic therapy.

Our psychedelic therapy program administers Ketamine IV infusions to rapidly relieve symptoms of depression and anxiety, including:
  • Persistent hopelessness
  • Excessive worry
  • Sleeplessness
  • Fatigue and low energy
  • Disinterest in social activities
  • Difficulty concentrating

What is Ketamine?

Ketamine is a dissociative anesthetic that can relieve symptoms of anxiety and depression by restoring circuits in the brain that have been impacted by depression and stress, and stimulating new neural connections.
Ketamine can also activate a dissociative experience and open your mind to new perspectives and insights.

Benefits of Ketamine IV Therapy

  • Fast Relief
  • Highest Safety Protocols
  • Backed by Research

Studies show single-dose ketamine reduces suicidal ideation as quickly as 2 hours after treatment.

Ketamine infusions are administered under the guidance of board-certified physicians.

Ketamine was cleared by the FDA as a safe anesthetic in 1970. Since then, numerous completed studies have proven its efficacy in facilitating targeted symptom relief and cognition improvement.

What to Expect

Ketamine can activate a dissociative experience that is often described as a “trip.”
During your treatment you may feel as though you have stepped outside of yourself and are detached from your body, thoughts, and memories. This dissociation creates space for you to experience yourself and your relationships from a new perspective.


$500 / Per Session

$2,500 / Package of 6

(recommended course by independent clinical trials, completed over 3-4 weeks)
*Ketamine is currently not covered by major insurance carriers. 


  1. Mandal S, Sinha VK, Goyal N. Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatry. 2019 Sep-Oct;61(5):480-485. doi: 10.4103/psychiatry.IndianJPsychiatry_484_18. PMID: 31579184; PMCID: PMC6767816.

  2. Xiong, Jiaqi et al. “The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.” Journal of psychiatric research vol. 134 (2021): 57-68. doi:10.1016/j.jpsychires.2020.12.038

  3. Gill, Hartej et al. “The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research.” Neuroscience and biobehavioral reviews vol. 120 (2021): 78-85. doi:10.1016/j.neubiorev.2020.11.020